Found: 10
Select item for more details and to access through your institution.
Subventricular zone involvement is associated with worse outcome in glioma WHO grade 2 depending on molecular markers.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-97714-5
- By:
- Publication type:
- Article
PD-1 blockade does not improve efficacy of EpCAM-directed CAR T-cell in lung cancer brain metastasis.
- Published in:
- Cancer Immunology, Immunotherapy, 2024, v. 73, n. 12, p. 1, doi. 10.1007/s00262-024-03837-9
- By:
- Publication type:
- Article
CAR T-Cells for CNS Lymphoma: Driving into New Terrain?
- Published in:
- Cancers, 2021, v. 13, n. 10, p. 2503, doi. 10.3390/cancers13102503
- By:
- Publication type:
- Article
Significance of molecular diagnostics for therapeutic decision-making in recurrent glioma.
- Published in:
- Neuro-Oncology Advances, 2023, v. 5, n. 1, p. 1, doi. 10.1093/noajnl/vdad060
- By:
- Publication type:
- Article
Shunt dependency in supratentorial intraventricular tumors depends on the extent of tumor resection.
- Published in:
- Acta Neurochirurgica, 2023, v. 165, n. 4, p. 1053, doi. 10.1007/s00701-023-05532-7
- By:
- Publication type:
- Article
AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas.
- Published in:
- Neurological Research & Practice, 2022, v. 4, n. 1, p. 1, doi. 10.1186/s42466-022-00184-x
- By:
- Publication type:
- Article
AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas.
- Published in:
- Neurological Research & Practice, 2022, p. 1, doi. 10.1186/s42466-022-00184-x
- By:
- Publication type:
- Article
Limited efficacy of temozolomide alone for astrocytoma, IDH-mutant, CNS WHO grades 2 or 3.
- Published in:
- Journal of Neuro-Oncology, 2022, v. 160, n. 1, p. 149, doi. 10.1007/s11060-022-04128-y
- By:
- Publication type:
- Article
Resection of glioma—Feeding the beast?
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 7, p. 1088, doi. 10.1093/neuonc/noac078
- By:
- Publication type:
- Article
Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas.
- Published in:
- Nature Communications, 2020, v. 11, n. 1, p. 1, doi. 10.1038/s41467-020-14642-0
- By:
- Publication type:
- Article